+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
1224844-38-5,MFCD22124893
Catalog No.:AA00177U

1224844-38-5 | Ink-128

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥98%
in stock  
$45.00   $31.00
- +
5mg
≥98%
in stock  
$88.00   $61.00
- +
10mg
≥98%
in stock  
$150.00   $105.00
- +
25mg
95%
in stock  
$300.00   $210.00
- +
50mg
≥98%
in stock  
$315.00   $220.00
- +
1g
98%
in stock  
$3,124.00   $2,187.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00177U
Chemical Name:
Ink-128
CAS Number:
1224844-38-5
Molecular Formula:
C15H15N7O
Molecular Weight:
309.3259
MDL Number:
MFCD22124893
SMILES:
Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
Properties
Computed Properties
 
Complexity:
436  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
23  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0  
Rotatable Bond Count:
2  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
1.7  

Literature

Title: Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.

Journal: Oncotarget 20160209

Title: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

Title: The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Journal: Nature 20120222

Title: ATP-competitive inhibitors of mTOR: an update.

Journal: Current medicinal chemistry 20110101

Title: mTOR Mediated Anti-Cancer Drug Discovery.

Journal: Drug discovery today. Therapeutic strategies 20090101

Title: Liu A, et al. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discovery Today: Therapeutic Strategies. 2009, 6(2), 47-55.

Title: Hsieh AC, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012 Feb 22;485(7396):55-61.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 1224844-38-5
2001571-40-8

2001571-40-8

 1887095-80-8

1887095-80-8
Building Blocks
More >
Tags:1224844-38-5 Molecular Formula|1224844-38-5 MDL|1224844-38-5 SMILES|1224844-38-5 Ink-128
Catalog No.: AA00177U
1224844-38-5,MFCD22124893
1224844-38-5 | Ink-128
Pack Size： 1mg
Purity： ≥98%
in stock
$45.00 $31.00
Pack Size： 5mg
Purity： ≥98%
in stock
$88.00 $61.00
Pack Size： 10mg
Purity： ≥98%
in stock
$150.00 $105.00
Pack Size： 25mg
Purity： 95%
in stock
$300.00 $210.00
Pack Size： 50mg
Purity： ≥98%
in stock
$315.00 $220.00
Pack Size： 1g
Purity： 98%
in stock
$3,124.00 $2,187.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00177U
Chemical Name: Ink-128
CAS Number: 1224844-38-5
Molecular Formula: C15H15N7O
Molecular Weight: 309.3259
MDL Number: MFCD22124893
SMILES: Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
Properties
Complexity: 436  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 23  
Hydrogen Bond Acceptor Count: 7  
Hydrogen Bond Donor Count: 2  
Isotope Atom Count: 0  
Rotatable Bond Count: 2  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 1.7  
Literature fold

Title: Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.

Journal: Oncotarget20160209

Title: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20120501

Title: The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Journal: Nature20120222

Title: ATP-competitive inhibitors of mTOR: an update.

Journal: Current medicinal chemistry20110101

Title: mTOR Mediated Anti-Cancer Drug Discovery.

Journal: Drug discovery today. Therapeutic strategies20090101

Title: Liu A, et al. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discovery Today: Therapeutic Strategies. 2009, 6(2), 47-55.

Title: Hsieh AC, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012 Feb 22;485(7396):55-61.

Related Products of of 1224844-38-5
2001571-40-8
2001571-40-8
1887095-80-8
1887095-80-8
Building Blocks More >
122684-35-9
122684-35-9
N-BOC-Pyrrolidine-3-thiocarboxamide
AA0017KH | MFCD03791259
138148-60-4
138148-60-4
4-(Methyldisulfanyl)butanoic acid
AA0017YY | MFCD20639700
13826-35-2
13826-35-2
3-Phenoxybenzyl alcohol
AA0018CF | MFCD00004636
138716-31-1
138716-31-1
2-Bromo-5-(isoxazol-5-yl)thiophene
AA0018ZE | MFCD03618406
13878-54-1
13878-54-1
Zinc, bis(1-piperidinecarbodithioato-κS1,κS1')-, (T-4)-
AA0019HU | MFCD00067344
13908-43-5
13908-43-5
1-(2-Chloroethyl)-1-(4-cyanophenyl)urea
AA001A38 | MFCD08689732
1392804-08-8
1392804-08-8
8-Bromo-3-chloro-[1,2,4]triazolo[4,3-a]pyridine
AA001AKH | MFCD23106210
139443-40-6
139443-40-6
Ethyl 3-ethyl-1,2,4-oxadiazole-5-carboxylate
AA001AYJ | MFCD08275043
139755-95-6
139755-95-6
7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-3-propyl-
AA001BLB | MFCD00908398
14005-14-2
14005-14-2
2,2-Dimethyl-1,3-benzodioxole
AA001BVO | MFCD08061594
Submit
© 2017 AA BLOCKS, INC. All rights reserved.